+950.4%
PLTR vs MRNA
+27.9%
+922.5%
-48.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | +0.7% | -2.9% | -2.2% |
| 7D | -9.1% | -8.2% | -0.9% | -8.7% |
| 30D | -5.2% | +125.6% | -130.7% | -14.5% |
| 3M | +27.4% | +197.1% | -169.7% | +9.4% |
| 6M | +9.7% | +148.5% | -138.8% | -3.3% |
| YTD | -6.7% | +363.3% | -370.0% | -26.8% |
| 1Y | -0.5% | +462.0% | -462.5% | -25.5% |
| All | +950.4% | +27.9% | +922.5% | +862.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling